SEC Comment Letter 0000000000-26-008092 to Cue Biopharma, Inc. (CUE) (CIK 0001645460) (CUE)
Cue Biopharma, Inc. (CUE) (CIK 0001645460)
Date: Aug. 17, 2026 · CIK: 0001645460 · Accession: 0000000000-26-008092
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-298266
Letter
Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed August 12, 2026 File No. 333-298266 Dear Shao-Lee Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions.
August 17, 2026
Shao-Lee Lin President and Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Courtney M.W. Tygesson, Esq.
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
August 17, 2026
Shao-Lee Lin
President and Chief Executive Officer
Cue Biopharma, Inc.
40 Guest Street
Boston, Massachusetts 02135
Re: Cue Biopharma, Inc.
Registration Statement on Form S-3
Filed August 12, 2026
File No. 333-298266
Dear Shao-Lee Lin:
This is to advise you that we have not reviewed and will not review your
registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Courtney M.W. Tygesson, Esq.
</TEXT>
</DOCUMENT>